N/A
N=122
Vitamin D in HIV-Infected Patients on HAART
Vitamin D Deficiency · HIV
Bottom Line
View on ClinicalTrials.gov: NCT01250899 ↗Enrolled (actual)
122
Serious AEs
0.0%
Results posted
Sep 2014
Primary outcome: Primary: Success Rate in Achieving a 25(OH)D Level ≥30ng/mL After 12 Weeks of Oral Vitamin D Supplementation. — 81 percentage of participants — p=<0.05
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Vitamin D (Dietary_supplement)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of California, Los Angeles
- Primary completion
- Jun 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Success Rate in Achieving a 25(OH)D Level ≥30ng/mL After 12 Weeks of Oral Vitamin D Supplementation. |
81 | <0.05 sig |
Summary
This is a research study to look at vitamin D deficiency (low levels) in men and women with HIV. As part of your regular medical care, you will be screened for vitamin D deficiency. If your levels are low, and you choose to start using vitamin D supplements, the investigators would like to take some blood before and after you start using vitamin D to see how this affects your levels of HIV, T cells, cholesterol, and other blood levels. The investigators will provide you with vitamin D supplements for the first 24 weeks (6 months) of the study. If you and your physician decide that you should continue taking vitamin D supplements after that time, you will be responsible for purchasing your own vitamin D supplements.
Eligibility Criteria
Inclusion Criteria
- HIV-positive men and women age 18 and older.
- HIV-1 RNA documented to be 200 copies/mL in the 6 months prior to screening).
Data sourced from ClinicalTrials.gov (NCT01250899). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.